Table 2.

New mutations detected following gilteritinib therapy

GeneNumber of patients (%) n = 41
RAS/MAPK pathway15 (36.6)
NRAS13 (31.7)
KRAS3 (7.3)
PTPN113 (7.3)
CBL2 (4.9)
BRAF1 (2.4)
FLT3-F691L5 (12.2)
WT12 (4.9)
CEBPA1 (2.4)
IDH21 (2.4)
RUNX11 (2.4)
TBL1XR11 (2.4)
  • NOTE: An additional 2 subjects had new BCR–ABL1 fusions detected at the time of progression on gilteritinib. Note that mutations are not mutually exclusive; many subjects had 2 new mutations detected.